NO992008D0 - New (+) enantiomers of cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes - Google Patents
New (+) enantiomers of cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromesInfo
- Publication number
- NO992008D0 NO992008D0 NO992008A NO992008A NO992008D0 NO 992008 D0 NO992008 D0 NO 992008D0 NO 992008 A NO992008 A NO 992008A NO 992008 A NO992008 A NO 992008A NO 992008 D0 NO992008 D0 NO 992008D0
- Authority
- NO
- Norway
- Prior art keywords
- syndromes
- estrogen
- enantiomers
- cis
- prevention
- Prior art date
Links
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940011871 estrogen Drugs 0.000 title 1
- 239000000262 estrogen Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK120296 | 1996-10-28 | ||
| PCT/DK1997/000482 WO1998018775A1 (en) | 1996-10-28 | 1997-10-28 | Novel (+)-enantiomers of cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO992008D0 true NO992008D0 (en) | 1999-04-27 |
| NO992008L NO992008L (en) | 1999-06-25 |
Family
ID=8102133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO992008A NO992008L (en) | 1996-10-28 | 1999-04-27 | New (+) enantiomers of cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0934298A1 (en) |
| JP (1) | JP2001502707A (en) |
| AU (1) | AU4771997A (en) |
| CA (1) | CA2269970A1 (en) |
| IL (1) | IL129624A0 (en) |
| NO (1) | NO992008L (en) |
| WO (1) | WO1998018775A1 (en) |
| ZA (1) | ZA979644B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1041258B (en) * | 1998-12-30 | 2003-12-12 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| CO5251465A1 (en) | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | COMPOSITIONS AND PROCEDURES TO TREAT OSTEOPOROSIS AND REDUCE CHOLESTEROL |
| US8080675B2 (en) | 2004-09-21 | 2011-12-20 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
| WO2006032085A1 (en) | 2004-09-21 | 2006-03-30 | Novogen Research Pty Ltd | Substituted chroman derivatives, medicaments and use in therapy |
| AU2008229617A1 (en) * | 2007-03-16 | 2008-09-25 | Novogen Research Pty Ltd | Method for inducing autophagy |
| EP2635273B1 (en) | 2010-11-01 | 2020-01-08 | MEI Pharma, Inc. | Isoflavonoid compositions and methods for the treatment of cancer |
| AU2016215515B2 (en) | 2015-02-02 | 2020-04-30 | Mei Pharma, Inc. | Combination therapies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3340276A (en) * | 1964-04-01 | 1967-09-05 | Ciba Geigy Corp | 3, 4-diphenyl-chromans |
| DE1543749A1 (en) * | 1966-02-16 | 1969-12-11 | Merck Ag E | Process for the preparation of 3,4-cis-4-aryl-isoflavans |
| US5280040A (en) * | 1993-03-11 | 1994-01-18 | Zymogenetics, Inc. | Methods for reducing bone loss using centchroman derivatives |
| HUP9702244A3 (en) * | 1995-01-13 | 1999-12-28 | Novo Nordisk As | Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders |
-
1997
- 1997-10-18 ZA ZA9709644A patent/ZA979644B/en unknown
- 1997-10-28 AU AU47719/97A patent/AU4771997A/en not_active Abandoned
- 1997-10-28 JP JP10519941A patent/JP2001502707A/en active Pending
- 1997-10-28 EP EP97910263A patent/EP0934298A1/en not_active Withdrawn
- 1997-10-28 IL IL12962497A patent/IL129624A0/en unknown
- 1997-10-28 WO PCT/DK1997/000482 patent/WO1998018775A1/en not_active Ceased
- 1997-10-28 CA CA002269970A patent/CA2269970A1/en not_active Abandoned
-
1999
- 1999-04-27 NO NO992008A patent/NO992008L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0934298A1 (en) | 1999-08-11 |
| NO992008L (en) | 1999-06-25 |
| JP2001502707A (en) | 2001-02-27 |
| ZA979644B (en) | 1998-04-28 |
| WO1998018775A1 (en) | 1998-05-07 |
| CA2269970A1 (en) | 1998-05-07 |
| IL129624A0 (en) | 2000-02-29 |
| AU4771997A (en) | 1998-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO944857D0 (en) | Fluorenyl-containing metallocenes, process for their preparation and process for polymerization of olefins using the metallocenes | |
| FI921260A0 (en) | PROCEDURE FOR THE PROCESSING OF PROFILES. | |
| DK0760238T3 (en) | Preparation that can be administered percutaneously for the treatment of urinary disorders | |
| NO864241L (en) | PROCEDURE FOR BLACKING CELLULOSMASS OR FRAGMENT THEREOF, PLANT FOR USE BY IMPLEMENTATION OF THE PROCEDURE AND SCREW PRESSURE, SPECIFICALLY FOR USE BY THE PROCEDURE UNDER THE APPLICATION. | |
| NO20004151D0 (en) | Iron dextran compound for use as a component in a therapeutic composition for profile ash or treatment of iron deficiency, a process for the preparation of the iron dextran compound and the use of the compound for the preparation of a parent compound | |
| EE03242B1 (en) | Method of continuous boiling of must, method of making beer from this must and beer produced by this method | |
| NO306943B1 (en) | Process for the preparation of the enantiomers of O-demethyltramadol | |
| NO911956L (en) | PROCEDURE FOR THE PREPARATION OF OXYDANT SENSITIVE AND INSENSITIVE, AROMATIC ESTERS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | |
| NO992010D0 (en) | New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes | |
| NO992008D0 (en) | New (+) enantiomers of cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes | |
| NO992009D0 (en) | New trans-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes | |
| NO992005D0 (en) | New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes | |
| NO171484C (en) | APPLICATION OF SUGARCARCOOL, POLYOXYLYCYLENETS OR ETHMONOSACCHARIDE OR MIXTURES THEREOF BASED FOR SOMATOSTATINES AND CALCITONINES FOR AA INCREASED BIOTAILABILITY OF THE PEPTIDES ORAL OR RECTAL. | |
| NO992003L (en) | New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes | |
| NO992002D0 (en) | New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes | |
| NO992006L (en) | New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes | |
| NO992004D0 (en) | New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes | |
| NO992007L (en) | Novel (-) Enantiomers of cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes | |
| NO985535D0 (en) | Process for the preparation of 1,3-alkanediols | |
| NO990283D0 (en) | Formulation for the treatment and / or prophylaxis of dementia | |
| NO963129D0 (en) | New Leukotriene B4 Derivatives, Methods of Preparation thereof and their Use as Drugs | |
| ITMI972622A1 (en) | DERIVATIVES OF 2-PHENYLAZULENE AND METHOD FOR THE PRODUCTION OF THESE COMPOUNDS | |
| NO985558D0 (en) | New improved formulation for the treatment of thromboembolism | |
| FI960698A0 (en) | For example, the dehydrogenation of the alkane and the catalyst can be used | |
| FI935236A0 (en) | After treatment, the absorbent absorbent solvent is used |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |